For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Rituximab - Immune thrombocytopenia
PAD Profile : Rituximab - Immune thrombocytopenia
Traffic Light Status
Status 1 of 1.
Guidelines
The following guidelines are available for this indication.
Other Drugs
Other Indications
- Refractory vasculitis
- Rheumatoid arthritis
- Systemic Lupus Erythematosus
- Sjogren's syndrome
- Chronic inflammatory demyelinating polyneuropathy
- Any paediatric use
- ANCA-positive vasculitis
- Connective tissue disease
- Graft versus Host Disease (GVHD)
- Myositis
- Immunoglobulin G4 related disease
Additional Documents
No additional documents returned.
Committee Recommendations
Rituximab is off-label for this indication. Prescribing to be retained by hospital specialists only.
Added 10/01/2025 for clarity.
‘Rituximab will be considered RED on the traffic light system. Prescribing will be by hospital specialists only. Please note: a pathway for the use of thrombopoietin receptor agonists (TPO-RAs) and fostamatinib in the treatment of immune thrombocytopenia in adults is available in the guidelines section of the PAD’.
The Medicines and Healthcare Products Regulatory Agency (MHRA) recommends to prescribe biological products by brand name to ensure that substitution of a biosimilar product does not occur when the medicine is dispensed by the pharmacist. Https://www/gov/uk/drug-safety-update/biosimilar-products
Primary care prescriber should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient's medication.
Associated BNF Codes
No BNF codes returned.